All articles by GlobalData Healthcare

Top 20 biopharmas’ market cap rises 6% in Q1 2025 amid tariff headwinds

The top 20 biopharmaceutical companies demonstrated a strong start to 2025, despite ongoing uncertainty surrounding the potential impact of President…
The 7MM atopic dermatitis market to experience growth, reaching $22.4bn by 2033

Atopic dermatitis (AD) is a widespread, chronic inflammatory skin condition that can affect patients of all ages and is the…
Do in vivo CAR-T cell therapies have the potential to overtake ex vivo CAR-Ts?

Chimeric antigen receptor (CAR) T-cell therapies have drastically changed treatment paradigms in relapsed and refractory (R/R) haematological malignancies since the…
ESCMID Global 2025: Climate-informed infectious disease risk management

At the 35th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Vienna, Austria, the development of…
COPD market projected to grow to $30.2bn in the 7MM by 2033

The chronic obstructive pulmonary disease (COPD) market across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and…

AAN 2025: Long-term outcome data on steroid regimens in MG may guide treatment standards

On 7 April, at the 2025 American Academy of Neurology (AAN) meeting, a poster presentation by the Peking Union Medical…
AD/PD 2025: Reporting of first real-world data for Leqembi focuses on operational challenges and safety

Following the launch of the first disease-modifying therapies for Alzheimer’s disease, a key theme at the AD/PD 2025 International Conference…
AD/PD 2025: First real-world data report for Leqembi focuses on operational challenges

Following the launch of the first disease-modifying therapies for Alzheimer’s disease, a key theme at the AD/PD 2025 International Conference…
Uveitis market expected to reach $1.5bn across 7MM by 2033

The uveitis market is expected to grow at a compound annual growth rate of 10.9% throughout the forecast period (2023…
IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility

Chimeric antigen receptor (CAR) T cell therapies have made remarkable strides in treating high-risk B-cell malignancies since the first CAR-T,…